De Novo Malignancies After Liver Transplantation: Experience of a High-Volume Center

Basit Öğe Kaydı
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridÖĞÜT, ZEKİ/0000-0002-7698-9586
dc.authoridSaglam, Kutay/0000-0002-0919-8370
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authorwosidince, volkan/M-7325-2017
dc.authorwosidÖĞÜT, ZEKİ/IZP-6632-2023
dc.authorwosidSaglam, Kutay/ACN-1173-2022
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.contributor.authorSaglam, Kutay
dc.contributor.authorSahin, Tevfik Tolga
dc.contributor.authorOgut, Zeki
dc.contributor.authorInce, Volkan
dc.contributor.authorUsta, Sertac
dc.contributor.authorYilmaz, Sezai
dc.date.accessioned2024-08-04T20:50:52Z
dc.date.available2024-08-04T20:50:52Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose Patient care, newer immunosuppressive medications, and advances in surgical technique, have resulted in significant prolongation of survival after liver transplantation in recent years. However, as life expectancy increased and the early mortality rates have decreased, different problems have evolved due to chronic immunosuppressive therapy. The aim of the present study is to evaluate patients who were transplanted and then developed de novo malignancies, in terms of the type of malignancies and the follow-up period. Methods The study was conducted on 2814 patients who received liver transplantation between 2008 and 2020 in Inonu University Liver Transplant Institute. In total, the data of 23 patients were evaluated retrospectively. Results Non-melanoma skin cancer was the most common de novo malignancy (21.7%), followed by gynecological cancers (17.3%). The interval between the time of transplantation until the development of de novo malignancy was 36 (6-75) months. The median follow-up period after the diagnoses of the de novo malignancies was 4.11 years. One, 3-, 5-year survival rates of patients after the diagnoses of de novo malignancies were 69.6%, 56.5%, and 41.9%; respectively. Conclusion Non-melanotic skin cancers were the most common de novo cancers in liver transplant recipients. A strict surveillance program is very important in the follow-up of liver transplant recipients.en_US
dc.identifier.doi10.1007/s12029-021-00749-0
dc.identifier.endpage1027en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid34778909en_US
dc.identifier.scopus2-s2.0-85119298708en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1020en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-021-00749-0
dc.identifier.urihttps://hdl.handle.net/11616/100314
dc.identifier.volume53en_US
dc.identifier.wosWOS:000718217400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDe novoen_US
dc.subjectHepaticen_US
dc.subjectImmunosuppressionen_US
dc.subjectCanceren_US
dc.titleDe Novo Malignancies After Liver Transplantation: Experience of a High-Volume Centeren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu